Reversal of aplastic anaemia secondary to systemic lupus erythematosus by high-dose intravenous cyclophosphamide
- 18 September 1982
- Vol. 285 (6344) , 769-770
- https://doi.org/10.1136/bmj.285.6344.769
Abstract
Aplastic anaemia is rare as a primary feature of systemic lupus erythematosus and is more commonly a complication of treatment with cytotoxic drugs. Three years after starting treatment for systemic lupus erythematosus a 22-year-old woman developed bone-marrow depression. Azathioprine was thought to be responsible and was withdrawn. The aplastic anaemia worsened despite treatment with prednisolone. In view of clinical and serological evidence of lupus disease activity the patient was given high-dose intravenous cyclophosphamide and the aplastic anaemia responded in a sustained manner. In such cases of continued disease activity high-dose immunosuppressive agents may prove effective.This publication has 6 references indexed in Scilit:
- T lymphocytes involved in inhibition of granulopoiesis in two neutropenic patients are of the cytotoxic/suppressor (T3+T8+) subset.Journal of Clinical Investigation, 1981
- Serum inhibitors of hematopoiesis in a patient with aplastic anemia and systemic lupus erythematosusThe American Journal of Medicine, 1979
- Autologous Bone Marrow Repopulation following High Dose Cyclophosphamide and Allogeneic Marrow Transplantation in Aplastic AnaemiaBritish Journal of Haematology, 1977
- Autoimmune PanleukopeniaNew England Journal of Medicine, 1976
- Autologous Marrow Reconstitutions in Severe Aplastic Anaemia after ALG Pretreatment and HL-A Semi-Incompatible Bone Marrow Cell TransfusionActa Haematologica, 1976